YouTube Facebook LinkedIn Google+ Twitter Xingrss  

News Blast


Aug 15, 2005

CALPAIN CONFIRMED
A recent New England Journal of Medicine article substantiated CepTor Corporation’s platform technology in the areas of Duchenne muscular dystrophy (DMD) and multiple sclerosis, verifying the role of calpain as a known causative in both conditions and touting calpain inhibition as a viable therapy. CepTor’s lead product, Myodur, targets DMD.

 LUCKY STROKE
Albany Molecular Research Inc. (AMRI) announced a two-year research collaboration with the National Institute of Neurological Disorders and Stroke to develop treatments for spinal muscular atrophy, a degenerative neuromuscular disease. AMRI will provide fee-for-service medicinal chemistry lead optimization on target compounds, including design and synthesis of analogs and analysis of associated structure activity relationships.

ILLUMINATION
San Diego-based Illumina began commercial shipment of its Sentrix Human-1 Genotyping BeadChip, which can interrogate more than 100,000 SNP loci per sample. This SNP content strategy is powered by Illumina’s Infinium assay, a genotyping method that  offers virtually unconstrained locus selection and scalable assay multiplexing.


Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.